A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Gonçalves, Anthony ^a,b,c   Esteyries, Séverine ^a,b,c   Taylor Smedra, Brynn ^a,b,c   Lagarde, Arnaud ^a,c   Ayadi, Mounay ^a   Monges, Geneviève ^a,b,c   Bertucci, François ^a,b,c   Esterni, Benjamin ^a,c   Delpero, Jean Robert ^a,b,c   Turrini, Olivier ^a   Lelong, Bernard ^a   Viens, Patrice ^a,b,c   Borg, Jean Paul ^a,b,c   Birnbaum, Daniel ^a,b,c   Olschwang, Sylviane ^a,c   Viret, Frédéric ^a,c  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MITOMYCIN C; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EXON; FATALITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; GENE NUMBER; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER SURGERY; LOADING DRUG DOSE; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; POSTOPERATIVE CARE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; TUMOR LOCALIZATION; COLORECTAL TUMOR; ENZYMOLOGY; GENE DOSAGE; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; EXONS; FEMALE; GENE DOSAGE; GENES, RAS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 45949083997     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-169     Document Type: Article

References (29)

1. Yarden Y Sliwkowski MX Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2001, 2(2):127-137. 10.1038/35052073 11252954
2. Cunningham D Humblet Y Siena S Khayat D Bleiberg H Santoro A Bets D Mueser M Harstrick A Verslype C Chau I Van Cutsem E Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 2004, 351(4):337-345. 10.1056/ NEJMoa033025 15269313
3. Van Cutsem E Peeters M Siena S Humblet Y Hendlisz A Neyns B Canon JL Van Laethem JL Maurel J Richardson G Wolf M Amado RG Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 2007, 25(13):1658-1664. 10.1200/JCO.2006.08.1620 17470858
4. Saltz LB Meropol NJ Loehrer PJ Sr. Needle MN Kopit J Mayer RJ Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor J Clin Oncol 2004, 22(7):1201-1208. 10.1200/JCO.2004.10.182 14993230
5. Lenz HJ Van Cutsem E Khambata-Ford S Mayer RJ Gold P Stella P Mirtsching B Cohn AL Pippas AW Azarnia N Tsuchihashi Z Mauro DJ Rowinsky EK Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines J Clin Oncol 2006, 24(30):4914-4921. 10.1200/ JCO.2006.06.7595 17050875
6. Schrag D The price tag on progress--chemotherapy for colorectal cancer N Engl J Med 2004, 351(4):317-319. 10.1056/NEJMp048143 15269308
7. Lynch TJ Bell DW Sordella R Gurubhagavatula S Okimoto RA Brannigan BW Harris PL Haserlat SM Supko JG Haluska FG Louis DN Christiani DC Settleman J Haber DA Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938 15118073
8. Paez JG Janne PA Lee JC Tracy S Greulich H Gabriel S Herman P Kaye FJ Lindeman N Boggon TJ Naoki K Sasaki H Fujii Y Eck MJ Sellers WR Johnson BE Meyerson M EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 2004, 304(5676):1497-1500. 10.1126/ science.1099314 15118125
9. Pao W Miller V Zakowski M Doherty J Politi K Sarkaria I Singh B Heelan R Rusch V Fulton L Mardis E Kupfer D Wilson R Kris M Varmus H EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 2004. 516528 15329413
10. Barber TD Vogelstein B Kinzler KW Velculescu VE Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 2004, 351(27):2883. 10.1056/NEJM200412303512724 15625347
11. Chung KY Shia J Kemeny NE Shah M Schwartz GK Tse A Hamilton A Pan D Schrag D Schwartz L Klimstra DS Fridman D Kelsen DP Saltz LB Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry J Clin Oncol 2005, 23(9):1803-1810. 10.1200/JCO.2005.08.037 15677699
12. Moroni M Veronese S Benvenuti S Marrapese G Sartore-Bianchi A Di Nicolantonio F Gambacorta M Siena S Bardelli A Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study Lancet Oncol 2005, 6(5):279-286. 10.1016/S1470-2045(05)70102-9 15863375
13. Lievre A Bachet JB Le Corre D Boige V Landi B Emile JF Cote JF Tomasic G Penna C Ducreux M Rougier P Penault-Llorca F Laurent-Puig P KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 2006, 66(8):3992-3995. 10.1158/ 0008-5472.CAN-06-0191 16618717
14. Di Fiore F Blanchard F Charbonnier F Le Pessot F Lamy A Galais MP Bastit L Killian A Sesboue R Tuech JJ Queuniet AM Paillot B Sabourin JC Michot F Michel P Frebourg T Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 2007, 96(8):1166-1169. 10.1038/sj.bjc.6603685 17375050
15. Khambata-Ford S Garrett CR Meropol NJ Basik M Harbison CT Wu S Wong TW Huang X Takimoto CH Godwin AK Tan BR Krishnamurthi SS Burris HA III Poplin EA Hidalgo M Baselga J Clark EA Mauro DJ Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab J Clin Oncol 2007, 25(22):3230-3237. 10.1200/JCO.2006.10.5437 17664471
16. Benvenuti S Sartore-Bianchi A Di Nicolantonio F Zanon C Moroni M Veronese S Siena S Bardelli A Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 2007, 67(6):2643-2648. 10.1158/0008-5472.CAN-06-4158 17363584
17. Frattini M Saletti P Romagnani E Martin V Molinari F Ghisletta M Camponovo A Etienne LL Cavalli F Mazzucchelli L PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients Br J Cancer 2007, 97(8):1139-1145. 10.1038/sj.bjc.6604009 17940504
18. WHO handbook for reporting of cancer treatment. Pathologie Biologie Geneva (Switzerland), World Health Organisation Offset Publication 1979, 48.
19. Chung CH Ely K McGavran L Varella-Garcia M Parker J Parker N Jarrett C Carter J Murphy BA Netterville J Burkey BB Sinard R Cmelak A Levy S Yarbrough WG Slebos RJ Hirsch FR Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas J Clin Oncol 2006, 24(25):4170-4176. 10.1200/JCO.2006.07.2587 16943533
20. Sartore-Bianchi A Moroni M Veronese S Carnaghi C Bajetta E Luppi G Sobrero A Barone C Cascinu S Colucci G Cortesi E Nichelatti M Gambacorta M Siena S Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab J Clin Oncol 2007, 25(22):3238-3245. 10.1200/JCO.2007.11.5956 17664472
21. Shia J Klimstra DS Li AR Qin J Saltz L Teruya-Feldstein J Akram M Chung KY Yao D Paty PB Gerald W Chen B Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: An immunohistochemical and chromogenic in situ hybridization study Mod Pathol 2005, 18(10):1350-1356. 10.1038/modpathol.3800417 15832190
22. Sauer T Guren MG Noren T Dueland S Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): A surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology 2005, 47(6):560-564. 10.1111/j.1365-2559.2005.02252.x 16324192
23. Al-Kuraya K Novotny H Bavi PP Siraj AK Uddin S Ezzat A Al Sanea N Al-Dayel F Al-Mana H Sheikh SS Mirlacher M Tapia C Simon R Sauter G Terracciano L Tornillo L HER2, TOP2A, CCND1, EGFR, And C-MYC oncogene amplification in colorectal cancer J Clin Pathol 2006. jcp.2006.038281
24. Li S Schmitz KR Jeffrey PD Wiltzius JJW Kussie P Ferguson KM Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 2005, 7(4):301-311. 10.1016/j.ccr.2005.03.003 15837620
25. Moriai T Kobrin MS Korc M Cloning of a variant epidermal growth factor receptor Biochem Biophys Res Commun 1993, 191(3):1034-1039. 10.1006/ bbrc.1993.1321 8466482
26. Wang WS Chen PM Chiou TJ Liu JH Lin JK Lin TC Wang HS Su Y Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma Clin Cancer Res 2007, 13(12):3597-3604. 10.1158/1078-0432.CCR-06-2601 17575224
27. Lassman AB Rossi MR Raizer JJ Abrey LE Lieberman FS Grefe CN Lamborn K Pao W Shih AH Kuhn JG Wilson R Nowak NJ Cowell JK DeAngelis LM Wen P Gilbert MR Chang S Yung WA Prados M Holland EC Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 Clin Cancer Res 2005, 11(21):7841-7850. 10.1158/ 1078-0432.CCR-05-0421 16278407
28. Zhang W Stoehlmacher J Park DJ Yang D Borchard E Gil J Tsao-Wei DD Yun J Gordon M Press OA Rhodes K Groshen S Lenz HJ Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer Clin Colorectal Cancer 2005, 5(2):124-131. 16098254
29. Moriai T Kobrin MS Hope C Speck L Korc M A Variant Epidermal Growth Factor Receptor Exhibits Altered Type {alpha} Transforming Growth Factor Binding and Transmembrane Signaling PNAS 1994, 91(21):10217-10221. 44989 7937865 10.1073/pnas.91.21.10217